Inova, the market-leading partnering platform for the pharmaceutical and biotech industry, today announced that Claude Basset has joined their leadership team as Chief Product Officer.
Rigel Pharmaceuticals announced enrollment of the first patients in a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19 patients.